NYU LANGONE HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1841-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.nyulangone.org
NYU Ovarian Cancer Early Detection Program Blood and Genetics
Terminated
- Conditions
- Ovarian Cancer
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 890
- Registration Number
- NCT00531778
- Locations
- 🇺🇸
NYUCancer Institute Clinical Cancer Center, New York, New York, United States
Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma
Completed
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 100
- Registration Number
- NCT00531570
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase 2
Completed
- Conditions
- Brain Tumors
- Interventions
- Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 46
- Registration Number
- NCT00528437
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center (MDACC), Houston, Texas, United States
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Phase 2
Completed
- Conditions
- Cocaine Dependence
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 100
- Registration Number
- NCT00527683
- Locations
- 🇲🇽
Clinica Integral de Tratamiento Contra las Adicciones SA de CV, Mexico City, Mexico, D.F., Mexico
Remote Simultaneous Medical Interpreting and Medical Outcomes
Not Applicable
Completed
- Conditions
- DIabetes
- Interventions
- Other: remote simultaneous medical interpretingOther: ENglish speakingOther: usual and customary
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 1200
- Registration Number
- NCT00522327
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Phase 2
Completed
- Conditions
- Atypical Endometrial HyperplasiaEndometrial Carcinoma
- Interventions
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 31
- Registration Number
- NCT00483327
- Locations
- 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸NYU Cancer Center, New York, New York, United States
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2
Terminated
- Conditions
- Pemphigus Vulgaris
- Interventions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 9
- Registration Number
- NCT00483119
- Locations
- 🇺🇸
NYU Medical Center, New York, New York, United States
Hirschsprung Disease Genetic Study
Recruiting
- Conditions
- Hirschsprung Disease
- Interventions
- Other: Identification of genetic causes of Hirschsprung Disease
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3000
- Registration Number
- NCT00478712
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
Phase 4
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 62
- Registration Number
- NCT00468143
- Locations
- 🇺🇸
VANYHHS, New York, New York, United States
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 24
- Registration Number
- NCT00463840
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath